{"aliases":[{"type":"USBrandName","name":"Tevimbra"},{"type":"Synonym","name":"anti-PD-1 monoclonal antibody BGB-A317"},{"type":"CodeName","name":"BGB-A317"},{"type":"CASRegistryName","name":"1858168-59-8"},{"type":"Synonym","name":"tirelizumab"},{"type":"Synonym","name":"tislelizumab"}],"definition":{"html":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab-jsgr binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.","text":"A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab-jsgr binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/tislelizumab-jsgr","text":"Tislelizumab-jsgr"},"nciConceptId":"C121775","nciConceptName":"Tislelizumab","termId":770893,"name":"tislelizumab-jsgr","firstLetter":"t","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"tislelizumab"}